The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Children's Oncology Group
Abstract
BACKGROUND.: Effective chemotherapy is lacking for most types of central nervous system (CNS) tumors in children. Temozolomide, an agent with activity against adult brain tumors, was investigated in children and adolescents with recurrent CNS tumors. METHODS.: Temozolomide was administered orally as monthly 5‐day courses at doses of 200 mg/m 2 /d (patients with no prior craniospinal irradiation [CSI]) or 180 mg/m 2 /d (prior CSI). Patients with a complete (CR) or partial (PR) response or stable disease (SD) could continue temozolomide for up to 12 cycles. RESULTS.: The cohort comprised 122 patients, including 113 with CNS tumors. Median age was 11 years (range, 1–23 years). Among 104 evaluable patients with CNS tumors, 5 PRs and 1 CR were observed. PRs occurred in 1 of 23 evaluable patients with high‐grade astrocytoma, 1 of 21 with low‐grade astrocytoma, and 3 of 25 with medulloblastoma/primitive neuroectodermal tumor (PNET). The CR occurred in an additional patient with medulloblastoma/PNET. No responses were observed in patients with ependymoma, brain‐stem glioma, or other CNS tumors. Notably, 41% of patients with low‐grade astrocytoma had SD through 12 courses. The most frequent toxicities were grade 3 or 4 neutropenia (19%) and thrombocytopenia (25%); nonhematologic toxicity was infrequent. CONCLUSIONS.: Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low‐grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929
Self-citationMulticenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372 · cited 1×
“Hematological Thrombocytopenia None 60 (51) 43 (48) 2 28 (24) 30 (34) 3 13 (11) 6 (7) 4 16 (14) 10 (11) Neutropenia None 67 (57) 52 (58) 2 28 (24) 23 (26) 3 7 (6) 8 (9) 4 15 (13) 6 (7) Nonhematological Nausea None 65 (56) 59 (66) 2 47 (40) 29 (33) 3 5 (4) 1 (1) 4 0 0 (0) Vomiting None 68 (58) 56 (63) 2 46 (39) 31 (35)…”
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S., Butowski, N., Campian, J. L., Clark, S. W., Fabiano, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0052 · Cited by 539
Ater, J. L., Zhou, T., Holmes, E., Mazewski, C. M., Booth, T. N., Freyer, D. R., Lazarus, K. H., Packer, R. J., Prados, M., Sposto, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.6054 · Cited by 433
Self-citationCNS complications of radiotherapy and chemotherapy
Soussain, C., Ricard, D., Fike, J. R., Mazeron, J.-J., Psimaras, D., & Delattre, J.-Y. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61299-x · Cited by 410
Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management
Sturm, D., Pfister, S. M., & Jones, D. T. W. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0242 · Cited by 339
Metadata
- Authors
- Nicholson, H. S., Kretschmar, C. S., Krailo, M., Bernstein, M., Kadota, R., Fort, D., Friedman, H., Harris, M. B., Tedeschi‐Blok, N., Mazewski, C., Sato, J., & Reaman, G. H.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-08-17
- Volume
- 110
- Issue
- 7
- Pages
- 1542-1550
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2054172055
- Cited by
- 196
- References
- 3
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Children's Oncology Group. https://app.cochat.ai/papers/10.1002/cncr.22961
- The paper
- Nicholson, H. S., Kretschmar, C. S., Krailo, M., Bernstein, M., Kadota, R., Fort, D., Friedman, H., Harris, M. B., Tedeschi‐Blok, N., Mazewski, C., Sato, J., & Reaman, G. H. (2007). Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Children's Oncology Group. Cancer. https://doi.org/10.1002/cncr.22961
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.